Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Normal saline placebo refers to the 0.9% sodium chloride solution used as the inactive control arm in the MAGiC (Magnesium for Children in Crisis) trial. This randomized, double-blind, Phase 2/3 study was conducted by the Medical College of Wisconsin in collaboration with the Pediatric Emergency Care Applied Research Network (PECARN) to evaluate the efficacy of intravenous magnesium sulfate in shortening the duration of vasoocclusive pain crises in children and young adults with sickle cell disease. The placebo was administered intravenously at a dose of 1 ml/kg (up to 60 ml) every 8 hours for a total of 6 doses. The trial results indicated that the addition of magnesium did not provide a significant clinical benefit over the normal saline placebo in terms of hospital length of stay or opioid requirements.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on normal saline placebo (Medical College of Wisconsin).